1Adam O,Neuberger HR,Bohm M.Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A roduc-tase inhibitors[J].Circulation,2008,118(12):1 285-1 293.
2Ramasubbu K,Estep J,White DL,et al.Experimental and clinical basis for the use of statins in patients with is chemic and nonis chemic cardiomyopatby[J].Am J coll Cardiol,2008,51 (4):415-426.
3Habibi J,Whaley-Cennell A,Qezi MA,et al.Rosuvastatin,a 3-hydroxyl-3-metbylglutaryl cocnzyme A roductase inhibitor,decreases cardiac oxidative stress and remodeling in Ben2 transgenic rats[J].Endocrinology,2007,148(5):2 181-2 188.
4Reiss AB,Wirkowski E.Roie of HMG-CoA reductase inhibitors in neurological disorders:progress to dete[J].Drugs,2007,67 (15):2 111-2 120.
5Undas A,Brummel KE,Musial J,et al.Simvastotin depresses blood clotting by inhibiting activation of prothrombin,factor V,and factorx Ⅲ and by enhancing factor Vainactivation[J].Circulation,2001,103:2 248-2 253.
6Gruaszi M,Belletti S,Lenatti L,et al.Effects of cardioversion of atrial fibrillation on endothelial function in hypertension or diabetes[J].Eur J Clin Invest,2007,37(1):26-34.
7Goldberger JJ,Subacius H,Schaechter A,et al.Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy[J].J Am Coll Cardiol,2006,48(6):1 228-1 233.
8Adam O,Frost G,Custodis F,et al.Role of RacI GTPase activation in atrial fibrillation[J].J Am Coil Cardiol,2007,50(4):359-367.
9Marin F,Pascual DA,Roldan V,et al.Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting[J].Am J Cardiol,2006,97(1):55-60.
10Wojnicz R,Wilczek K,Nowaleny-Kozielska E,et al.Usefulness of atorvastalin in patients with heart failure due to inflammatory dilated cardiomyopatby and elevated cholesterol levels[J].Am J Cardiol,2006,97(6):899-904.
同被引文献9
1Liao J, Farmer JA. Statins as adjunctive therapy in the management of hy- pertension [ J ]. Curr Atheroseler Rep, 2010,12 (5) : 349 - 354.
2Kostapanos MS, Milionis HJ, Elisaf MS. Current role of statins in the treat- ment of essential hypertension[J]. Expert Opin Pharmacother, 2010, 11(16): 2 635 -2 650.
3Di Napoli P, Taccardi AA, Grilli A, et al. Chronic treatment with rosuvas- tatin modulates nitric oxide synthase expression and reduces ischemia- repeffusion injury in rat hearts[./]. Cardiovasc Res, 2005,66(3): 462- 471.
4Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide [ J ]. Circ Res, 2005,97(12): 1 232 - 1235.
5Sarkar K, Sinha AK, Mehta JL. The role of statins in endothelial dysfunction in hypertension [ J ]. Curr Opin Cardiol, 2006,21 (4) : 316 - 321.
6Rev Med Liege. First evidence of greater cardiovascular protective effects of newer as compared to old antihypertensive drugs treatments: the ASCOT - BPLA results [ J ]. Krzesinski JM, 2005,60 (10) : 820 - 826.
7Feldstein CA. Statins in hypertension: are they a new class of antihyper- tensive agents [ J ]. Am J Ther, 2010,17 ( 3 ) : 255 - 262.
